Health Care & Life Sciences » Pharmaceuticals | Mithra Pharmaceuticals

Mithra Pharmaceuticals S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,561.00
1,678.00
96,794.00
45,750.00
36,190.00
118,949
Total Accounts Receivable
4,112.00
3,367.00
8,914.00
7,542.00
33,323.00
23,772
Inventories
2,413.00
1,763.00
2,797.00
4,170.00
4,141.00
10,945
Other Current Assets
17.00
1,371.00
584.00
414.00
558.00
1
Total Current Assets
8,103.00
8,179.00
109,089.00
57,876.00
74,212.00
153,667
Net Property, Plant & Equipment
1,455.00
2,407.00
3,573.00
16,961.00
59,519.00
84,396
Total Investments and Advances
214.00
2,119.00
198.00
165.00
-
-
Intangible Assets
1,725.00
2,181.00
86,250.00
84,363.00
85,618.00
87,140
Other Assets
250.00
247.00
1,132.00
1,138.00
2,645.00
3,203
Total Assets
11,904.00
15,696.00
205,587.00
172,696.00
244,712.00
355,684
ST Debt & Current Portion LT Debt
3,446.00
3,573.00
17,854.00
6,955.00
16,237.00
Accounts Payable
2,581.00
3,544.00
4,613.00
9,312.00
16,141.00
Income Tax Payable
916.00
311.00
43.00
73.00
11.00
Other Current Liabilities
1,234.00
1,094.00
12,030.00
11,365.00
19,850.00
Total Current Liabilities
8,177.00
8,522.00
34,540.00
27,705.00
52,217.00
Long-Term Debt
1,239.00
1,650.00
37,695.00
48,242.00
103,247.00
Provision for Risks & Charges
-
-
266.00
265.00
267.00
Deferred Taxes
157.00
563.00
347.00
8,724.00
20,619.00
Total Liabilities
9,416.00
10,172.00
78,193.00
79,681.00
157,830.00
Common Equity (Total)
2,488.00
5,524.00
127,394.00
93,015.00
86,882.00
Total Shareholders' Equity
2,488.00
5,524.00
127,394.00
93,015.00
86,882.00
Total Equity
2,488.00
5,524.00
127,394.00
93,015.00
86,882.00
Liabilities & Shareholders' Equity
11,904.00
15,696.00
205,587.00
172,696.00
244,712.00

About Mithra Pharmaceuticals

View Profile
Address
Rue Saint-Georges 5
Liege WA 4000
Belgium
Employees -
Website http://www.mithra.com
Updated 07/08/2019
Mithra Pharmaceuticals SA engages in the development, manufacture, and commercialization of proprietary and differentiated drugs and generic products dedicated to female healthcare. It specializes in the following domains of health for women: contraception and fertility, menopause and osteoporosis, gynecological infections, and cancers. The company was founded by Jean-Michel Foidart and François Fornieri on July 8, 1999 and is headquartered in Liège, Belgium.